# 68Ga-DOTA-TATE PET/CT Imaging in NETs

Source: https://onco.cc/trials/nct04847505/  
OnCo record `nct04847505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently.

## Summary

68Ga-DOTA-TATE PET/CT Imaging in NETs is a phase 3 interventional study registered as NCT04847505 by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with 5000 participants planned, started 2020-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: 68Ga-DOTA-TATE. Conditions recorded: Neuroendocrine Tumors.

Linked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04847505
- Phase: 3
- Setting: Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management
- Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Enrolled: 5000

## Sources

- ClinicalTrials.gov NCT04847505: https://clinicaltrials.gov/study/NCT04847505

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://onco.cc/drugs/ga68-dotatate/)

---
JSON: https://onco.cc/api/v1/entities/nct04847505.json